TY - BOOK AU - Soudan ,Hadeer Magdy Ahmed Ali AU - Hammad ,Sherif AU - Ghazy ,Mohamed AU - Soliman ,Mahmoud AU - Fath El-Bab ,Ahmed AU - Kamel ,Amany Osama AU - Abdel Wahab ,Abdel Hady Ali AU - Hammad ,Sherif AU - Ghazy ,Mohamed AU - حماد ، شریف ، AU - غازي ، محمد ، AU - سليمان ، محمود ، AU - فتح الباب ، أحمد ، AU - كامل ، أماني أسامة ، AU - عبدالوهاب ، عبدالهادي على ، AU - حماد ، شریف ، AU - غازي ، محمد ، TI - Evaluation of the Repurposing Potential of Remdesivir for Non - Small Cell Lung Cancer : : A Thesis Submitted to the Graduate School of Basic and Applied Sciences (BAS) Institute : Egypt-Japan University of Science and Technology (E-JUST) : In Partial Fulfilment of the Requirements for the Degree of Doctor of Philosophy in Biotechnology / AV - EPE PhD. 2025 01 PY - 2024/// CY - Alexandria : PB - Hadeer Magdy Ahmed Ali Soudan N1 - Includes a title page in Arabic; Thesis (Ph.D.); Includes bibliographical references ; Issued also as a digital file (for more information please check our Digital Repository) N2 - Lung cancer remains the leading cause of cancer-related mortality worldwide, with non-small cell lung cancer (NSCLC) comprising approximately 85% of cases. Regrettably, most NSCLC diagnoses occur at advanced stages (III or IV), where treatment options are largely limited to radiotherapy and chemotherapy Although patients initially respond to these treatments, drug resistance frequently emerges, diminishing long-term efficacy This highlights a critical need for novel therapeutics with enhanced efficacy and safety profiles. Drug repurposing has gained attention as an innovative approach that uses existing approved or investigational drugs to treat diseases beyond their original indications, reducing research costs and shortening development timelines. The known safety profiles and preclinical data of these drugs accelerate the approval process for new uses. In this context, remdesivir (RDV), a recently approved antiviral drug, was investigated for its potential anticancer activity against NSCLC cell lines. RDV targets viral RNA- dependent RNA polymerase (RdRP), which shares molecular and phylogenetic similarities with human telomerase reverse transcriptase (hTERT), the catalytic core of the telomerase enzyme This suggests RDV may serve as a promising inhibitor of telomerase activity in cancerous tissues RDV was loaded into biocompatible liposomes (RDV-Lips) composed of 1,2 dipalmitoyl - sn-glycero-3-phosphocholine (DPPC), cholesterol, and polyethylene glycol hexadecyl ether (Brij-58) to enhance its solubility and anticancer efficiency RDV-Lips were developed using thin-film hydration and then subjected to physicochemical characterizations. The selected formulations were evaluated for their stability, in vitro release, and in vitro anticancer activity The size range of RDV-Lips was 83.8-157.9 nm with a polydispersity index (PDI) lower than 0.23 and entrapment exceeded 93% Altering the cholesterol content of RDV-Lips offered a control point of RDV release, where increasing the concentration from 2.5% to 25% 10-fold) shifted the release profile from fast to slow release. RDV-Lips showed enhanced anticancer activity against A549 and H460 cells NSCLC cell lines, with selective toxicity toward cancer cells over normal human skin fibroblasts (HSF) cells. RDV-Lips inhibited colony formation, increased lipid peroxidation, induced apoptosis, and inhibited the telomerase activity in a dose-dependent manner. Moreover, in silico molecular docking analysis indicated that RDV binds to both viral RdRP and hTERT with comparable binding energies of -8.42 and -8.00 kcal/mol, respectively In conclusion, RDV Lips effectively overcame RDV's solubility limitations and enhanced its anticancer efficacy highlighting RDV's potential as a therapeutic against NSCLC. The anticancer effects likely result ER -